SAB: Human polyclonal antibodies on the hoof

SAB uses cows, goats to overcome limitations of generating polyclonal antibodies

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies.

Therapeutic mAbs and bi- and tri-specific antibodies target no more than three epitopes, and their Fc domains define and limit whether or how they modulate complement, cellular immune responses and other immune system features. By contrast, “the polyclonal response is already suited very well for activation of the entire immune system,” Eddie Sullivan,

Read the full 774 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE